Kamada : Advancement in its Phase II Trial with Aerosolized AAT to treat CF: First Group of Patients Completes Treatment

March 19, 2008 - Kamada, a biopharmaceutical company developing, manufacturing and marketing specialty, life-saving therapeutics, announces of an advancement in the company's Phase II clinical trial to test the efficacy of its aerosolized AAT (Alpha-1 Antitrypsin) product delivered via an optimized eFlow electronic nebulizer (PARI Pharma) to treat Cystic Fibrosis (CF). The first group of patients has completed treatment with a satisfactory safety profile and with no special adverse events. The trial is ongoing, according to original planned timelines, with the company's aim to complete it by the end of 2008... Kamada 's Press Release -